Skip to main content
editorial
. 2015 Feb;3(1):95–96. doi: 10.1177/2050640614560787

Table 2.

Study results

ADE Phase I (n = 34) Phase II (n = 27)
Dosing Schedule 2x(B140M125T125) +  A500 + E20 bid x10d 3x(B140M125T125) +  A500 + E20 bid x10d
Eradication success (ITT) 20/34 (59%) 17/27 (63%)
Eradication success (PP) 20/30 (67%) 17/26 (65%)
Any ADE 10 (29%) 9 (33%)

ADE: adverse drug events.